INDIAN HEALTHCARE SECTOR

Industry poised for year of strong growth

JULY 2021
Agenda

1. Industry Outlook and Demand
3. Operational and Financial Comparison
4. ICRA Ratings in the Sector
5. Company Section

www.icra.in
EXECUTIVE SUMMARY
Poised for a year of strong growth

Covid cases started re-surging in India in March 2021 and touched an all-time high on May 6, 2021

Occupancies likely to improve to 61-63% in FY2022, from 52.5% in FY2021 due to higher hospitalisations on account of second wave of Covid-19 and increase in number of elective procedures in FY2022 owing to lesser lockdown restrictions as well as higher vaccination coverage

- After recovering from the impact of the first wave of Covid-19, the revenues of companies in the sample set\(^1\) grew by a healthy 7% on QoQ basis in Q4 FY2021
- The operating margin expanded to a multi-year high of 18.4% in Q4 FY2021 on the back of substantial improvement in operating metrics as well as significant cost cutting measures undertaken
- Overall, revenues contracted by 5% in FY2021 while operating margins contracted to 12.5% in FY2021 from 14.8% in FY2020 due to significant impact of the pandemic in H1
- ICRA expects revenues to grow by 20-22% and EBITDA to expand by over 200bps in FY2022 on the back of lower base and tailwinds in the form of Covid-related hospitalisations and pent-up demand for critical procedures
- On the back of better accruals, interest coverage ratio is projected to rise to ~4.7x (from 2.6x) and Net debt/EBITDA is expected to improve to 1.36x in FY2022 (from 1.6x in FY2021)
- Tier-2 & 3 centres witnessed surge in volumes in FY2021 given the travel restrictions and the unwillingness to travel to tier-1 cities which had higher cases
- Long-term outlook for the industry continues to remain Stable given the increasing life expectancy, rising incidence of non-communicable lifestyle diseases, growing per capita spend, increasing penetration of health insurance, and robust medical tourism volumes

\(^1\): ICRA’s sample of companies includes Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Aster DM Healthcare Limited (India business only), Max Healthcare Institute Limited (previously part of Max India Limited), Healthcare Global Enterprises Limited, and Shalby Limited. Debt protection indicators are based on consolidated financials
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Kurian Eranat</td>
<td>Vice-President</td>
<td><a href="mailto:Mathew.eranat@icraindia.com">Mathew.eranat@icraindia.com</a></td>
<td>080 - 4332 6415</td>
</tr>
<tr>
<td>Kapil Banga</td>
<td>Assistant Vice-President</td>
<td><a href="mailto:kapil.banga@icraindia.com">kapil.banga@icraindia.com</a></td>
<td>0124 - 4545 391</td>
</tr>
<tr>
<td>Mythri Macherla</td>
<td>Assistant Vice-President</td>
<td><a href="mailto:mythri.macherla@icraindia.com">mythri.macherla@icraindia.com</a></td>
<td>080 – 4332 6407</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Email</td>
<td>Phone</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>L. Shivakumar</td>
<td>Executive Vice-President</td>
<td><a href="mailto:shivakumar@icraindia.com">shivakumar@icraindia.com</a></td>
<td>022-6114 3406</td>
</tr>
<tr>
<td>Jayanta Chatterjee</td>
<td>Executive Vice-President</td>
<td><a href="mailto:jayantac@icraindia.com">jayantac@icraindia.com</a></td>
<td>080–4332 6401</td>
</tr>
<tr>
<td>Naznin Prodhani</td>
<td>Head Media &amp; Communications</td>
<td><a href="mailto:communications@icraindia.com">communications@icraindia.com</a></td>
<td>0124–4545 860</td>
</tr>
</tbody>
</table>
All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.
Thank You!